We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1951
SkinHealth Systems
SKIN
$71.6M
| $2.22K | ﹤0.01% |
1,160
-166,147
| -99% | -$234K |
2024 Q1
5 quarters
|
|
1952
Vital Farms
VITL
$401M
| $2.2K | ﹤0.01% |
57
-27,104
| -100% | -$915K |
2020 Q3
19 quarters
|
|
1953
Bioventus
BVS
$892M
| $2.19K | ﹤0.01% |
+331
| New | +$2.35K |
2025 Q2
0 quarters
|
|
1954
DELISTED
Steelcase
SCS
| $2.19K | ﹤0.01% |
210
-64
| -23% | -$659 |
2024 Q4
2 quarters
|
|
1955
IDT Corp
IDT
$2.02B
| $2.12K | ﹤0.01% |
+31
| New | +$1.78K |
2025 Q2
0 quarters
|
|
1956
Preformed Line Products
PLPC
$1.94B
| $2.08K | ﹤0.01% |
13
| – | – |
2017 Q1
33 quarters
|
|
1957
Dakota Gold
DC
$816M
| $2.03K | ﹤0.01% |
+549
| New | +$1.72K |
2025 Q2
0 quarters
|
|
1958
eHealth
EHTH
$22.4M
| $1.97K | ﹤0.01% |
+452
| New | +$2.27K |
2025 Q2
0 quarters
|
|
1959
OptimizeRx
OPRX
$156M
| $1.92K | ﹤0.01% |
+142
| New | +$1.55K |
2025 Q2
0 quarters
|
|
1960
Tango Therapeutics
TNGX
$4.01B
| $1.85K | ﹤0.01% |
362
-7,221
| -95% | -$17.9K |
2025 Q1
1 quarter
|
|
1961
SelectQuote
SLQT
$64.2M
| $1.84K | ﹤0.01% |
+775
| New | +$2.03K |
2025 Q2
0 quarters
|
|
1962
Ponce Financial Group
PDLB
$485M
| $1.8K | ﹤0.01% |
+130
| New | +$1.68K |
2025 Q2
0 quarters
|
|
1963
AudioEye
AEYE
$87.1M
| $1.75K | ﹤0.01% |
150
| – | – |
2024 Q1
5 quarters
|
|
1964
Willis Lease Finance
WLFC
$864M
| $1.71K | ﹤0.01% |
36
| – | – |
2025 Q1
1 quarter
|
|
1965
Kalaris Therapeutics
KLRS
$56.2M
| $1.69K | ﹤0.01% |
634
| – | – |
2023 Q4
6 quarters
|
|
1966
Alto Neuroscience
ANRO
$956M
| $1.68K | ﹤0.01% |
+765
| New | +$1.82K |
2025 Q2
0 quarters
|
|
1967
Kura Oncology
KURA
$943M
| $1.68K | ﹤0.01% |
+291
| New | +$1.78K |
2025 Q2
0 quarters
|
|
1968
Viridian Therapeutics
VRDN
$2.11B
| $1.66K | ﹤0.01% |
+119
| New | +$1.61K |
2025 Q2
0 quarters
|
|
1969
Simply Good Foods
SMPL
$901M
| $1.64K | ﹤0.01% |
52
-29
| -36% | -$1.01K |
2024 Q3
3 quarters
|
|
1970
DELISTED
LivePerson
LPSN
| $1.6K | ﹤0.01% |
106
-109
| -51% | -$1.29K |
2023 Q1
9 quarters
|
|
1971
Firy Inc
FIRY
$201M
| $1.56K | ﹤0.01% |
+229
| New | +$1.27K |
2025 Q2
0 quarters
|
|
1972
DELISTED
GoHealth
GOCO
| $1.53K | ﹤0.01% |
276
+145
| +111% | +$1.15K |
2025 Q1
1 quarter
|
|
1973
Andersons Inc
ANDE
$2.17B
| $1.47K | ﹤0.01% |
40
-14
| -26% | -$513 |
2022 Q4
10 quarters
|
|
1974
Mission Produce
AVO
$1.03B
| $1.45K | ﹤0.01% |
+124
| New | +$1.34K |
2025 Q2
0 quarters
|
|
1975
Weis Markets
WMK
$1.81B
| $1.45K | ﹤0.01% |
20
-6
| -23% | -$470 |
2022 Q4
10 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.